Conference Coverage

MDR Candida auris is on the move


 

REPORTING FROM ECCMID 2018


A separate poster by Dr. Pemán and his colleagues gave more details:

• A 52-year-old woman with C. auris–induced endocarditis died after 4 weeks of treatment with AMB+ECN and flucytosine. She had undergone a prosthetic heart valve placement for Ebstein’s anomaly.

• A 71-year-old man with hydrocephalus developed a C. auris–induced infection of his ventriculoperitoneal shunt; he also had undergone cardiovascular surgery and had an ischemic cardiomyopathy. He died despite shunt removal and 8 weeks of AMB+ECN.

• A 71-year-old man who underwent cardiovascular surgery and received a prosthetic heart valve developed endocarditis. He is alive and at last report, on week 26 of AMB+ECN, flucytosine, and isavuconazole.

• A 68-year-old man who underwent abdominal surgery for hepatocellular carcinoma developed spondylodiscitis and is alive after 24 weeks of AMB+ECN.

• A 48-year old female multiple trauma patient developed spondylodiscitis and is alive after 48 weeks of treatment with AMB+ECN.

A multivariate analysis determined that antibacterial treatment increased the risk of candidemia by almost 30 times (odds ratio, 29.59). The next highest risk was neutropenia (OR, 20.7) and then simply being a hospital and SICU patient. Dr. Pemán’s poster said, “In the 16 months before the index case, La Fe recorded 89 candidemias, none caused by C. auris. In the 16 months afterward, there were 154 candidemias, largely C. auris. Before April 2016, C. parapsilosis accounted for the largest portion of candidemias (46%) followed by C. albicans. After the index case, C. auris accounted for 42%, followed by C. parapsilosis (21%) and C. albicans (18%).”

Because of its fluconazole resistance, patients with C. auris received a combined antifungal treatment of liposomal amphotericin B 3 mg/kg per day for 5 days, and a standard dose of echinocandin for 3 weeks. Many C. auris strains are echinocandin resistant, Dr. Pemán noted. This particular strain was clonal, different from any other previously reported, he said.

“Our results confirm those previously reported by other authors, that C. auris is grouped in different independent clusters according to its geographical origin. Although all Spanish isolates were genotypically distinct from Indian, Omani, U.K., and Venezuelan isolates, there seems to be some connection with South African isolates.”

Hospital Le Fe continues to struggle with C. auris. As of March, 335 patients have tested positive for the pathogen, and 80 have developed candidemias.

“We feel we may be approaching the end of this episode, but it’s really not possible to be sure,” he said.

Dr. Pemán had no relevant financial disclosures.

SOURCE: ECCMID 2018 Peman et al. S0067.

Pages

Recommended Reading

When to discontinue contact precautions for patients with MRSA
MDedge Dermatology
VA MRSA Prevention Initiative reports continued health care–associated infection declines
MDedge Dermatology
Hospital infections top WHO’s list of priority pathogens
MDedge Dermatology
Each added day of pediatric MRSA bacteremia upped complication risk 50%
MDedge Dermatology
FDA approves new fluoroquinolone for skin, skin structure infections
MDedge Dermatology
Antimicrobial development model links financial incentives with public health needs
MDedge Dermatology
High percentage of nursing home residents found to harbor MDROs
MDedge Dermatology
FDA warns against clarithromycin use in patients with heart disease
MDedge Dermatology
MDedge Daily News: Antibiotic resistance leads to ‘nightmare’ bacteria
MDedge Dermatology
Don’t shorten therapy for older, sicker cellulitis patients
MDedge Dermatology